

P&T Committee Meeting Minutes

Subject:	•
	Medicaid Pharmaceutical and Therapeutic Committee Meeting
Location:	628 North Fourth Street
	Baton Rouge, LA Bienville Building
	Room 118
	And Virtual TEAMS Webinar:
	https://events.teams.microsoft.com/event/ec638f64-3df4-474a-b954-
	4eeb622b722d@34c95ba7-5ec6-4527-bc5e-b33b58104992
Date:	October 30, 2024
Members Present:	■ Ben Orlando, RPh
	Dr. Jill Comeau
	■ Dr. Scott Black
	Dr. Julio E. Figueroa
	Dr. Mary C. Raven
	Dr. Tammy D. HartDr. Charles C. Coleman
	Dr. Charles C. ColemanSue Fontenot, RPh
LDH Pharmacy	Melwyn Wendt, PharmD
Program Staff	Haley Williams
Present:	Rachel Broussard, RPh
	Katrina Johnson
	Shantel Hebert-Magee
	Vanessa De La Cruz
Contractors Present:	
renesem.	Melissa Pelletier, Prime Therapeutics SGS (virtually)
	Caitlyn J. Connelly, Certified Court Reporter
Others Present:	Presenters are listed in the minutes and sign in sheets and others in attendance
	from LDH, Bureau of Health Services Financing, Pharmacy Benefits Section upon
	request.

Call to Order

Mr. Ben Orlando, Chairman, called the meeting to order at or around 9:00 am. He indicated quorum was established.

- A. Introduction of Members/Roll Call. Committee members, LDH staff, and contractors introduced themselves.
- B. Approval of Meeting Minutes. Dr. Black made the motion to accept the Minutes from the November 2022 meeting. Dr. Raven seconded the motion. There was no objection to the motion. Dr. Black made the motion to accept the Minutes from the May 2023 meeting. Dr. Raven seconded the motion. There was no objection to the motion. Dr. Black made the motion to accept the Minutes from the October 2023 meeting. Dr. Raven seconded the motion. There was no objection to the motion. Dr. Black made the motion to accept the Minutes from the April 2024 meeting. Dr. Raven seconded the motion. There was no objection to the motion.

P & T Committee Review Virtual Process

Dr Douiki indicated the meeting was being held in-person and virtually. For those who joined virtually, the slides being presented will be shared on the screen. Speakers will be muted unless unmuted by Melissa Pelletier. A timer of two minutes will be placed when a speaker provides public testimony.

Ethics

Ms. Williams went over several sections of the code of ethics. Members are bound by the governmental code of ethics. All committee members are required to complete the online ethics training every calendar year.

Reports

A. PDL Reflecting Spring 2024 Recommendations. Ms. Fontenot indicated the Brand Over Generic program was removed in July. LDH is recommending those Brands to be moved to nonpreferred and leave their generics preferred. Ms. Fontenot reminded the committee that the PDL is posted online along with the PA criteria for the nonpreferred drugs.

New Business

A. Explanation of TOP\$, Monographs and Cost Sheets

Dr. Douiki indicated Magellan Medicaid Administration is now Prime Therapeutics State Government Solutions (SGS). She provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in. She presented information about clinical and financial components of the recommendation process. Dr. Douiki also summarized the supplemental rebate process. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates...etc. The committee members should also have cost sheets which include relative values, rather than actual numbers, in order to comply with the privacy laws regarding rebates.

B. Therapeutic Class Reviews of Fall Drug Classes/Drug Manufacturer Testimony. In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

Presenter	Representing Drug/Issue
Mesellier	Representing Drughssue

7544-CD1 © 2025 Prime Therapeutics LLC 2

Ronnie DePue	Axsome	Auvelity and Sunosi
Payal Tejani	Biogen	Zurzuvae
Brett Stephenson	Arcutis	Zoryve cream and foam
Krista Bay	AstraZeneca	AirSupra
Tony Nelson	Johnson & Johnson	Tremfya
Kirk	Teva	Simlandi
Ann Porter	LSU Gastroenterology	Tremfya and Skyrizi
Jessie Cruz	Amgen	Tezspire
Erik Schindler and Jomy Joseph	Sanofi	Dupixent
Joe	Incyte	Opzelura
Kirk ·Latibeaudiere	Teva	Austedo
Shirley Quach	Novartis	Kisqali
[Name was not captured]	Medunik	Siklos and n Pheburane
**NOTE: Names of speakers	who were present and yielded the	heir time back were not captured.

Alzheimer's Agents

Dr. Comeau made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DONEPEZIL ODT (ORAL)
- DONEPEZIL TABLET (ORAL)
- MEMANTINE TABLET (AG) (ORAL)
- MEMANTINE TABLET (ORAL)
- RIVASTIGMINE (AG) (TRANSDERM.)
- RIVASTIGMINE (TRANSDERM.)
- RIVASTIGMINE CAPSULES (ORAL)

Anthelmintics

Dr. Figueroa made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALBENDAZOLE (ORAL)
- EMVERM (ORAL)
- IVERMECTIN (ORAL)
- PRAZIQUANTEL (ORAL)

Anti-Allergens, Oral

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

None (all products in this class are recommended NPD)

Anticonvulsants

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

- APTIOM (ORAL)
- BRIVIACT TABLET (ORAL)
- BRIVIACT SOLUTION (ORAL)
- CARBAMAZEPINE CHEWABLE TABLET (ORAL)
- CARBAMAZEPINE ER (CARBATROL) (ORAL)
- CARBAMAZEPINE TABLET (ORAL)
- CARBAMAZEPINE XR (ORAL)
- CELONTIN (ORAL)
- CLOBAZAM SUSPENSION (ORAL)
- CLOBAZAM TABLET (ORAL)
- CLONAZEPAM (ORAL)
- CLONAZEPAM ODT (ORAL)
- DIACOMIT CAPSULE (ORAL)
- DIACOMIT POWDER PACK (ORAL)
- DIAZEPAM (AG) (RECTAL)
- DIAZEPAM DEVICE (AG) (RECTAL)
- DILANTIN 30 MG CAPSULE (ORAL)
- DIVALPROEX ER (ORAL)
- DIVALPROEX SPRINKLE (ORAL)
- DIVALPROEX TABLET (ORAL)
- EPIDIOLEX (ORAL)

- LAMOTRIGINE DISPERSABLE TABLET (ORAL)
- LAMOTRIGINE TABLET (ORAL)
- LAMOTRIGINE XR (ORAL)
- LEVETIRACETAM ER (ORAL)
- LEVETIRACETAM SOLUTION (ORAL)
- LEVETIRACETAM TABLETS (ORAL)
- NAYZILAM (NASAL)
- OXCARBAZEPINE SUSPENSION (ORAL)
- OXCARBAZEPINE TABLETS (ORAL)
- OXTELLAR XR (ORAL)
- PHENOBARBITAL ELIXIR (ORAL)
- PHENOBARBITAL TABLET (ORAL)
- PHENYTOIN CAPSULE (ORAL)
- PHENYTOIN CHEWABLE TABLET (ORAL)
- PHENYTOIN EXT CAPSULE (GENERIC PHENYTEK) (ORAL)
- PHENYTOIN SUSPENSION (AG) (ORAL)
- PHENYTOIN SUSPENSION (ORAL)
- PRIMIDONE (ORAL)
- RUFINAMIDE SUSPENSION (ORAL)
- RUFINAMIDE TABLET (ORAL)
- SEZABY (INTRAVEN)

- ETHOSUXIMIDE CAPSULE (AG) (ORAL)
- ETHOSUXIMIDE CAPSULE (ORAL)
- ETHOSUXIMIDE SYRUP (ORAL)
- FELBAMATE SUSPENSION (ORAL)
- FELBAMATE TABLET (ORAL)
- FELBATOL TABLET (ORAL)
- FYCOMPA SUSPENSION (ORAL)
- FYCOMPA TABLET (ORAL)
- LACOSAMIDE SOLUTION (ORAL)
- LACOSAMIDE TABLET (ORAL)

- TOPIRAMATE ER (TROKENDI) (ORAL)
- TOPIRAMATE SPRINKLE (ORAL)
- TOPIRAMATE TABLETS (ORAL)
- VALPROIC ACID CAPSULE (ORAL)
- VALPROIC ACID SOLUTION (ORAL)
- VALTOCO (NASAL)
- VIGABATRIN POWDER PACK (ORAL)
- VIGABATRIN TABLET (ORAL)
- XCOPRI TABLET (ORAL)
- XCOPRI TITRATION PAK (ORAL)
- ZONISAMIDE (ORAL)

Antidepressants, Other

Dr. Raven made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BUPROPION (ORAL)
- BUPROPION SR (ORAL)
- BUPROPION XL (ORAL)
- DESVENLAFAXINE ER (PRISTIQ) (AG) (ORAL)
- DESVENLAFAXINE ER (PRISTIQ) (ORAL)
- MIRTAZAPINE ODT (ORAL)
- MIRTAZAPINE TABLET (ORAL)
- TRAZODONE (ORAL)
- VENLAFAXINE (ORAL)
- VENLAFAXINE ER CAPSULES (ORAL)

Antidepressants, SSRIs

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CITALOPRAM SOLUTION (ORAL)
- CITALOPRAM TABLET (ORAL)
- ESCITALOPRAM TABLET (ORAL)
- FLUOXETINE CAPSULE (ORAL)
- FLUOXETINE SOLUTION (ORAL)
- FLUVOXAMINE (ORAL)
- PAROXETINE TABLET (ORAL)
- SERTRALINE CONC (ORAL)
- SERTRALINE TABLET (ORAL)

Antihistamines, Minimally Sedating

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CETIRIZINE SOLUTION (ORAL)
- CETIRIZINE SOLUTION OTC (ORAL)
- CETIRIZINE TABLETS OTC (ORAL)
- CETIRIZINE-D OTC (ORAL)
- LEVOCETIRIZINE TABLETS (ORAL)
- LEVOCETIRIZINE TABLETS OTC (ORAL)
- LORATADINE ODT OTC (ORAL)
- LORATADINE SOLUTION OTC (ORAL)
- LORATADINE TABLETS OTC (ORAL)
- LORATADINE-D OTC (ORAL)

Antihypertensives, Sympatholytics

Dr. Figueroa made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CLONIDINE (ORAL)
- CLONIDINE (TRANSDERM)
- GUANFACINE (ORAL)
- METHYLDOPA (AG) (ORAL)
- METHYLDOPA (ORAL)

Antihyperuricemics

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALLOPURINOL (ORAL)
- COLCHICINE TABLET (AG) (ORAL)
- COLCHICINE TABLET (ORAL)
- FEBUXOSTAT (ORAL)
- PROBENECID (ORAL)
- PROBENECID / COLCHICINE (ORAL)

Antiparkinson's Agents

Dr. Coleman made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

- AMANTADINE CAPSULE (ORAL)
- AMANTADINE SYRUP (ORAL)
- BENZTROPINE (ORAL)
- CARBIDOPA / LEVODOPA (ORAL)
- CARBIDOPA / LEVODOPA ER (ORAL)
- CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)
- PRAMIPEXOLE (ORAL)
- ROPINIROLE (ORAL)
- SELEGILINE TABLET (ORAL)
- TRIHEXYPHENIDYL ELIXIR (ORAL)
- TRIHEXYPHENIDYL TABLET (ORAL)

Antipsoriatics, Oral

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ACITRETIN (AG) (ORAL)
- ACITRETIN (ORAL)

Antipsoriatics, Topical

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CALCIPOTRIENE CREAM (TOPICAL)
- CALCIPOTRIENE SOLUTION (TOPICAL)

Antipsychotics

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ABILIFY ASIMTUFII (INTRAMUSC)
- ABILIFY MAINTENA (INTRAMUSC.)
- AMITRIPTYLINE / PERPHENAZINE (ORAL)
 PALIPERIDONE (AG) (ORAL)
- ARIPIPRAZOLE TABLET (ORAL)
- ARISTADA (INTRAMUSC)
- ARISTADA INITIO (INTRAMUSC)
- CHLORPROMAZINE (ORAL)
- CLOZAPINE (ORAL)

- OLANZAPINE ODT (ORAL)
- OLANZAPINE TABLET (ORAL)
- PALIPERIDONE (ORAL)
- PERPHENAZINE (ORAL)
- PERSERIS (SUBCUTANEOUS)
- PIMOZIDE (ORAL)
- QUETIAPINE ER (ORAL)
- QUETIAPINE TABLETS (ORAL)

7544-CD1 © 2025 Prime Therapeutics LLC

- FLUPHENAZINE DECANOATE (INJECTION)
- FLUPHENAZINE TABLET (ORAL)
- HALOPERIDOL (ORAL)
- HALOPERIDOL DECANOATE (INJECTION)
- HALOPERIDOL LACTATE (INJECTION)
- HALOPERIDOL LACTATE CONC (ORAL)
- INVEGA HAFYERA (INTRAMUSC)
- INVEGA SUSTENNA (INTRAMUSC)
- INVEGA TRINZA (INTRAMUSC)
- LOXAPINE (ORAL)
- LURASIDONE (ORAL)

- RISPERDAL CONSTA (INTRAMUSC)
- RISPERIDONE (INTRAMUSC)
- RISPERIDONE SOLUTION (ORAL)
- RISPERIDONE TABLET (ORAL)
- THIORIDAZINE (ORAL)
- THIOTHIXENE (ORAL)
- TRIFLUOPERAZINE (ORAL)
- UZEDY (SUBCUTANEOUS)
- VRAYLAR (ORAL)
- ZIPRASIDONE (INTRAMUSC)
- ZIPRASIDONE CAPSULE (AG) (ORAL)
- ZIPRASIDONE CAPSULE (ORAL)

Anxiolytics

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALPRAZOLAM TABLET (ORAL)
- BUSPIRONE (ORAL)
- LORAZEPAM TABLET (ORAL)

Bile Salts

Dr. Coleman made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- URSODIOL TABLET (ORAL)
- URSODIOL 300 MG CAPSULE (ORAL)

Botulinum Toxins

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

- BOTOX (INTRAMUSC)
- DYSPORT (INTRAMUSC)

Bronchodilators, Beta Agonist

Dr. Comeau made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALBUTEROL HFA (PROAIR) (AG) (INHALATION)
- ALBUTEROL HFA (PROAIR) (INHALATION)
- ALBUTEROL HFA (PROVENTIL) (AG) (INHALATION)
- ALBUTEROL HFA (PROVENTIL) (INHALATION)
- ALBUTEROL HFA (VENTOLIN) (AG) (INHALATION)
- ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)
- SEREVENT (INHALATION)

Colony Stimulating Factors

Dr. Coleman made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FULPHILA (SUBCUTANEOUS)
- FYLNETRA (SUBCUTANEOUS)
- NEUPOGEN DISP SYRIN (INJECTION)
- NEUPOGEN VIAL (INJECTION)

COPD Agents

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ANORO ELLIPTA (INHALATION)
- ATROVENT HFA (INHALATION)
- COMBIVENT RESPIMAT (INHALATION)
- IPRATROPIUM / ALBUTEROL (INHALATION)
- IPRATROPIUM NEBULIZER (INHALATION)
- ROFLUMILAST (ORAL)
- STIOLTO RESPIMAT (INHALATION)
- TIOTROPIUM (INHALATION)

Cytokine and CAM Antagonists

Dr. Figueroa made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

- ADALIMUMAB-AATY KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-AATY PEN KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADAZ KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADAZ PEN KIT (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADBM KIT (BI) (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADBM KIT (BI) (INJECTION) (CF) 50 MG/ML
- ADALIMUMAB-ADBM PEN KIT (BI) (INJECTION) (CF) 100 MG/ML
- ADALIMUMAB-ADBM PEN KIT (BI) (INJECTION) (CF) 50 MG/ML
- CYLTEZO KIT (INJECTION) (CF) 100 MG/ML
- CYLTEZO KIT (INJECTION) (CF) 50 MG/ML
- CYLTEZO PEN KIT (INJECTION) (CF) 100 MG/ML
- CYLTEZO PEN KIT (INJECTION) (CF) 50 MG/ML
- ENBREL MINI CARTRIDGE (SUBCUTANE.)
- ENBREL PEN (INJECTION)
- ENBREL SYRINGE (INJECTION)
- ENBREL VIAL (SUBCUTANE.)
- HADLIMA KIT (INJECTION) (CF) 100 MG/ML
- HADLIMA KIT (INJECTION) 50 MG/ML
- HADLIMA PEN KIT (INJECTION) (CF) 100 MG/ML
- HADLIMA PEN KIT (INJECTION) 50 MG/ML
- HUMIRA KIT (INJECTION) (CF) 100 MG/ML
- HUMIRA KIT (INJECTION) 50 MG/ML
- HUMIRA PEN KIT (INJECTION) (CF) 100 MG/ML
- HUMIRA PEN KIT (INJECTION) 50 MG/ML
- INFLIXIMAB (INJECTION)
- OTEZLA (ORAL)
- XELJANZ (ORAL)
- YUSIMRY PEN KIT (INJECTION) (CF) 50 MG/ML

Emollients

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

AMMONIUM LACTATE CREAM/LOTION (TOPICAL)

Enzyme Replacement, Gaucher Disease

Dr. Figueroa made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

None (all products in this class are recommended NPD)

Epinephrine, Self-Injected

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AUVI-Q 0.1 MG (INTRAMUSC)
- AUVI-Q 0.15 MG (INTRAMUSC)
- AUVI-Q 0.3 MG (INTRAMUSC)
- EPINEPHRINE 0.15 MG (EPIPEN JR) (AG) (INJECTION)
- EPINEPHRINE 0.15 MG (EPIPEN JR) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (AG) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (INJECTION)
- EPIPEN (INTRAMUSC)
- EPIPEN JR (INTRAMUSC)

Erythropoiesis Stimulating Proteins

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ARANESP DISP SYRIN (INJECTION)
- ARANESP VIAL (INJECTION)
- EPOGEN (INJECTION)
- RETACRIT (INJECTION)

Glucocorticoids, Inhaled

Dr. Coleman made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

- ARNUITY ELLIPTA (INHALATION)
- ASMANEX (INHALATION)
- ASMANEX HFA (INHALATION)
- BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)
- BUDESONIDE 1 MG RESPULES (INHALATION)
- BUDESONIDE/FORMOTEROL (AG) (INHALATION)
- BUDESONIDE/FORMOTEROL (INHALATION)
- DULERA (INHALATION)
- FLOVENT HFA (INHALATION)
- FLUTICASONE HFA (AG) (INHALATION)
- FLUTICASONE/SALMETEROL (ADVAIR) (AG) (INHALATION)
- FLUTICASONE/SALMETEROL (ADVAIR) (INHALATION)
- FLUTICASONE/SALMETEROL HFA (AG) (INHALATION)

- QVAR REDIHALER (INHALATION)
- TRELEGY ELLIPTA (INHALATION)

Glucocorticoids, Oral

Dr. Comeau made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BUDESONIDE EC (ORAL)
- DEXAMETHASONE TABLET (ORAL)
- HYDROCORTISONE (ORAL)
- METHYLPREDNISOLONE TAB DS PK (ORAL)
- PREDNISOLONE SODIUM PHOSPHATE (ORAL)
- PREDNISOLONE SOLUTION (ORAL)
- PREDNISONE TABLET (ORAL)

Hemophilia Treatment

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ALPHANATE (INTRAVEN.)
- BENEFIX KIT (INTRAVEN.)
- COAGADEX (INTRAVEN)
- CORIFACT KIT (INTRAVEN)
- HEMLIBRA (SUBCUTANE.)
- HUMATE-P KIT (INTRAVEN.)
- JIVI (INTRAVEN)
- KOVALTRY (INTRAVEN.)
- NOVOEIGHT (INTRAVEN)
- NOVOSEVEN RT (INTRAVEN)
- NUWIQ (INTRAVEN)
- REBINYN (INTRAVEN)
- WILATE (INTRAVEN)
- XYNTHA KIT (INTRAVEN)
- XYNTHA SOLOFUSE SYRINGE KIT (INTRAVEN.)

Histamine II Receptor Blockers

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FAMOTIDINE SUSPENSION (ORAL)
- FAMOTIDINE TABLET (ORAL)

7544-CD1 © 2025 Prime Therapeutics ŁLC 12

Idiopathic Pulmonary Fibrosis

Dr. Raven made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- OFEV (ORAL)
- PIRFENIDONE CAPSULE (ESBRIET) (ORAL)
- PIRFENIDONE TABLET (ESBRIET) (ORAL)

Immune Globulins

Dr. Figueroa made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- GAMMAGARD LIQUID (INJECTION)
- GAMUNEX-C (INJECTION)
- HIZENTRA SYRINGE (SUBCUTANEOUS)
- HIZENTRA VIAL (SUBCUTANEOUS)

Immunomodulators, Asthma

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FASENRA PEN (SUBCUTANEOUS)
- FASENRA SYRINGE (SUBCUTANEOUS)
- XOLAIR SYRINGE (SUB-Q)
- XOLAIR VIAL (SUB-Q)

Immunomodulators, Atopic Dermatitis

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

- ADBRY AUTOINJECTOR (SUBCUTANEOUS)
- ADBRY SYRINGE (SUBCUTANEOUS)
- DUPIXENT PEN (SUBCUTANEOUS)
- DUPIXENT SYRINGE (SUBCUTANEOUS)
- EUCRISA (TOPICAL)
- OPZELURA (TOPICAL)
- PIMECROLIMUS (AG) (TOPICAL)

- PIMECROLIMUS (TOPICAL)
- TACROLIMUS (AG) (TOPICAL)
- TACROLIMUS (TOPICAL)

Immunomodulators, Lupus

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

• None (all products in this class are recommended NPD)

Immunomodulators, Topical

Dr. Raven made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

IMIQUIMOD (ALDARA) (TOPICAL)

Intranasal Rhinitis Agents

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AZELASTINE (ASTELIN)) (NASAL)
- FLUTICASONE (NASAL)
- IPRATROPIUM (NASAL)

Leukotriene Modifiers

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- MONTELUKAST CHEWABLE TABLET (ORAL)
- MONTELUKAST TABLET (ORAL)

Methotrexate

Dr. Raven made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

- METHOTREXATE PF VIAL (AG) (INJECTION)
- METHOTREXATE PF VIAL (INJECTION)

- METHOTREXATE TABLET (ORAL)
- METHOTREXATE VIAL (INJECTION)

Movement Disorders

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AUSTEDO (ORAL)
- AUSTEDO XR (ORAL)
- AUSTEDO XR TITR PK (ORAL)
- INGREZZA (ORAL)
- INGREZZA INITIATION PACK (ORAL)
- INGREZZA SPRINKLE (ORAL)
- TETRABENAZINE (ORAL)

Neuropathic Pain

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DULOXETINE (CYMBALTA) (ORAL)
- GABAPENTIN CAPSULE (ORAL)
- GABAPENTIN SOLUTION (AG) (ORAL)
- GABAPENTIN SOLUTION (ORAL)
- GABAPENTIN TABLET (ORAL)
- LIDOCAINE (AG) (TOPICAL)
- LIDOCAINE (TOPICAL)
- PREGABALIN CAPSULE (AG) (ORAL)
- PREGABALIN CAPSULE (ORAL)
- PREGABALIN SOLUTION (AG) (ORAL)
- PREGABALIN SOLUTION (ORAL)
- SAVELLA (ORAL)
- SAVELLA DOSE PACK (ORAL)

NSAIDS

Dr. Raven made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

- CELECOXIB (AG) (ORAL)
- CELECOXIB (ORAL)
- DICLOFENAC GEL (TOPICAL)
- DICLOFENAC SODIUM (ORAL)
- KETOROLAC (ORAL)
- MELOXICAM TABLET (ORAL)
- NABUMETONE (ORAL)
- NAPROXEN SUSPENSION (AG) (ORAL)

- IBUPROFEN SUSPENSION (ORAL)
- IBUPROFEN TABLET (ORAL)
- INDOMETHACIN CAPSULE (ORAL)
- NAPROXEN SUSPENSION (ORAL)
- NAPROXEN TABLET (ORAL)
- SULINDAC (ORAL)

Oncology, Oral - Breast

Dr. Comeau made the motion to add Kisqali as preferred and Ibrance as NPD. Dr. Figueroa seconded it. There was no objection to this motion. Dr. Black made the motion to accept the recommendations on the entire class. Dr. Raven seconded the motion. There was no objection to this motion.

Recommendations for the PDL are:

- ANASTROZOLE (ORAL)
- CAPECITABINE (ORAL)
- CYCLOPHOSPHAMIDE (ORAL)
- EXEMESTANE (ORAL)
- FULVESTRANT (AG) (INTRAMUSC)
- FULVESTRANT (INTRAMUSC)
- KISQALI (ORAL)
- LETROZOLE (ORAL)
- TAMOXIFEN CITRATE (ORAL)

Oncology, Oral - Hematologic

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- HYDROXYUREA (ORAL)
- IMATINIB (ORAL)
- IMBRUVICA CAPSULE (ORAL)
- IMBRUVICA TABLET (ORAL)
- JAKAFI (ORAL)
- LENALIDOMIDE (ORAL)
- MATULANE (ORAL)

- MERCAPTOPURINE (ORAL)
- REVLIMID (ORAL)
- SPRYCEL (ORAL)
- TRETINOIN (ORAL)
- VENCLEXTA (ORAL)
- VENCLEXTA STARTING PACK (ORAL)

Oncology, Oral - Lung

Dr. Comeau made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

- ALECENSA (ORAL)
- GILOTRIF (ORAL)
- HYCAMTIN (ORAL)
- TAGRISSO (ORAL)
- XALKORI (ORAL)

Oncology, Oral - Other

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- KOSELUGO (ORAL)
- TEMOZOLOMIDE (ORAL)

Oncology, Oral - Prostate

Dr. Raven made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ABIRATERONE (ORAL)
- BICALUTAMIDE (ORAL)
- XTANDI CAPSULE (ORAL)
- XTANDI TABLET (ORAL)

Oncology, Oral - Renal Cell

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- EVEROLIMUS TABLET (AFINITOR) (ORAL)
- INLYTA (ORAL)
- LENVIMA (ORAL)
- NEXAVAR (ORAL)
- PAZOPANIB TABLET (VOTRIENT) (ORAL)
- SORAFENIB (ORAL)
- SUNITINIB (ORAL)
- VOTRIENT (ORAL)

Oncology, Oral - Skin

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

17

Recommendations for the PDL are:

- COTELLIC (ORAL)
- MEKINIST (ORAL)
- ODOMZO (ORAL)
- TAFINLAR (ORAL)
- ZELBORAF (ORAL)

Ophthalmic Antibiotics

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)
- CIPROFLOXACIN SOLUTION (OPHTHALMIC)
- ERYTHROMYCIN (OPHTHALMIC)
- GENTAMICIN DROPS (OPHTHALMIC)
- MOXIFLOXACIN (AG) (VIGAMOX) (OPHTHALMIC)

- MOXIFLOXACIN (VIGAMOX) (OPHTHALMIC)
- NEOMYCIN-POLYMYXIN-GRAMICIDIN (OPHTHALMIC)
- OFLOXACIN (OPHTHALMIC)
- POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)
- SULFACETAMIDE SOLUTION (OPHTHALMIC)
- TOBRAMYCIN DROPS (OPHTHALMIC)

Ophthalmic Antibiotic/Steroid Combinations

Dr. Black made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)
- SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)
- TOBRADEX OINTMENT (OPHTHALMIC)
- TOBRADEX SUSPENSION (OPHTHALMIC)
- TOBRAMYCIN / DEXAMETHASONE SUSPENSION (AG) (OPHTHALMIC)
- TOBRAMYCIN / DEXAMETHASONE SUSPENSION (OPHTHALMIC)

Ophthalmics for Allergic Conjunctivitis

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

- ALREX (OPHTHALMIC)
- AZELASTINE (OPHTHALMIC)
- CROMOLYN SODIUM (OPHTHALMIC)
- LOTEPREDNOL (OPHTHALMIC)

OLOPATADINE (PATANOL) (OPHTHALMIC)

Ophthalmic Anti-inflammatories

Dr. Comeau made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DEXAMETHASONE (OPHTHALMIC)
- DICLOFENAC (OPHTHALMIC)
- DIFLUPREDNATE (AG) (OPHTHALMIC)
- DIFLUPREDNATE (OPHTHALMIC)
- **DUREZOL (OPHTHALMIC)**
- FLUOROMETHOLONE (OPHTHALMIC)
- FLURBIPROFEN (OPHTHALMIC)
- KETOROLAC (OPHTHALMIC)
- KETOROLAC LS (OPHTHALMIC)
- PREDNISOLONE ACETATE (OPHTHALMIC)

Ophthalmics, Anti-Inflammatory/Immunomodulator

Dr. Coleman made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CYCLOSPORINE (AG) (OPHTHALMIC)
- CYCLOSPORINE (OPHTHALMIC)
- XIIDRA (OPHTHALMIC)

Ophthalmics, Cystinosis

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

None (all products in this class are recommended NPD)

Ophthalmics, Glaucoma Agents

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

- BRIMONIDINE 0.15% (ALPHAGAN P 0.15%) RHOPRESSA (OPHTHALMIC) (OPHTHALMIC)

 - ROCKLATAN (OPHTHALMIC)

- BRIMONIDINE 0.2% (OPHTHALMIC)
- BRIMONIDINE TARTRATE/TIMOLOL DROPS (AG) (OPHTHALMIC)
- BRIMONIDINE TARTRATE/TIMOLOL DROPS (OPHTHALMIC)
- CARTEOLOL (OPHTHALMIC)
- DORZOLAMIDE (OPHTHALMIC)
- DORZOLAMIDE / TIMOLOL (OPHTHALMIC)
- LATANOPROST 2.5 ML (OPHTHALMIC)
- LEVOBUNOLOL (OPHTHALMIC)

- SIMBRINZA (OPHTHALMIC)
- TIMOLOL (OPHTHALMIC)
- TRAVATAN Z 2.5 ML (OPHTHALMIC)
- TRAVATAN Z 5 ML (OPHTHALMIC)
- TRAVOPROST 2.5 ML (AG) (OPHTHALMIC)
- TRAVOPROST 2.5 ML (OPHTHALMIC)
- TRAVOPROST 5 ML (AG) (OPHTHALMIC)
- TRAVOPROST 5 ML (OPHTHALMIC)

Otic Antibiotics

Dr. Figueroa made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- CIPROFLOXACIN/DEXAMETHASONE (AG) (OTIC)
- CIPROFLOXACIN/DEXAMETHASONE (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (AG) (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)
- OFLOXACIN (OTIC)

Otic Anti-infectives & Anesthetics

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ACETIC ACID (OTIC)
- ACETIC ACID HC (OTIC)

Progestational Agents

Dr. Black made the motion to accept. Dr. Hart seconded the motion. There was no objection to the motion.

- HYDROXYPROGESTERONE CAPROATE SINGLE DOSE VIAL (INTRAMUSCULAR)
- MEDROXYPROGESTERONE ACETATE (AG) (ORAL)
- MEDROXYPROGESTERONE ACETATE (ORAL)
- NORETHINDRONE ACETATE (ORAL)
- PROGESTERONE CAPSULE (ORAL)

Sedative Hypnotics

Dr. Coleman made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- ESZOPICLONE (ORAL)
- TEMAZEPAM (AG) (ORAL)
- TEMAZEPAM (ORAL)
- TRIAZOLAM (ORAL)
- ZOLPIDEM (ORAL)
- ZOLPIDEM ER (ORAL)

Sickle Cell Anemia Treatments

Dr. Black made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- DROXIA (ORAL)
- HYDROXYUREA (ORAL)
- · SIKLOS (ORAL)

Smoking Cessation

Dr. Black made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BUPROPION SR (ORAL)
- CHANTIX (ORAL)
- CHANTIX DOSE PACK (ORAL)
- NICOTINE GUM OTC (BUCCAL)
- NICOTINE LOZENGE OTC (BUCCAL)
- NICOTINE PATCH OTC (TRANSDERMAL)
- VARENICLINE DOSE PACK (ORAL)
- VARENICLINE TARTRATE (ORAL)

Spinal Muscular Atrophy

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

ZOLGENSMA (INTRAVENOUS)

Steroids Topical, High

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- BETAMET DIPROP / PROP GLY CREAM (TOPICAL)
- BETAMETHASONE VALERATE CREAM (TOPICAL)
- BETAMETHASONE VALERATE LOTION (TOPICAL)
- BETAMETHASONE VALERATE OINTMENT (TOPICAL)
- TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)
- TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)
- TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)

Steroids Topical, Low

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- HYDROCORTISONE CREAM (RECTAL)
- HYDROCORTISONE CREAM (TOPICAL)
- HYDROCORTISONE LOTION (TOPICAL)
- HYDROCORTISONE OINTMENT (TOPICAL)

Steroids Topical, Medium

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- FLUTICASONE PROPIONATE CREAM (TOPICAL)
- FLUTICASONE PROPIONATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE CREAM (TOPICAL)
- MOMETASONE FUROATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE SOLUTION (TOPICAL)

Steroids Topical, Very High

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

- CLOBETASOL EMOLLIENT (TOPICAL)
- CLOBETASOL PROPIONATE CREAM (TOPICAL)
- CLOBETASOL PROPIONATE GEL (TOPICAL)
- CLOBETASOL PROPIONATE OINTMENT (TOPICAL)

- CLOBETASOL PROPIONATE SOLUTION (TOPICAL)
- HALOBETASOL PROPIONATE CREAM (TOPICAL)
- HALOBETASOL PROPIONATE OINTMENT (TOPICAL)

Stimulants and Related Agents

Dr. Coleman made the motion to accept. Dr. Black seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

- AMPHETAMINE SALT COMBO (ORAL)
- AMPHETAMINE SALT COMBO ER (AG) (ORAL)
- AMPHETAMINE SALT COMBO ER (ORAL)
- ATOMOXETINE (ORAL)
- DEXMETHYLPHENIDATE (ORAL)
- DEXMETHYLPHENIDATE ER (ORAL)
- DEXTROAMPHETAMINE TABLET (ORAL)
- GUANFACINE ER (ORAL)
- LISDEXAMFETAMINE CAPSULE (ORAL)
- LISDEXAMFETAMINE CHEWABLE TABLET VYVANSE CAPSULE (ORAL) (ORAL)
- METHYLPHENIDATE (ORAL)

- METHYLPHENIDATE CD (AG) (ORAL)
- METHYLPHENIDATE CD (ORAL)
- METHYLPHENIDATE ER (CONCERTA) (AG) (ORAL)
- METHYLPHENIDATE ER (CONCERTA) (ORAL)
- METHYLPHENIDATE ER (RITALIN LA) (ORAL)
- METHYLPHENIDATE SOLUTION (ORAL)
- MODAFINIL (ORAL)

Thrombopoiesis Stimulating Proteins

Dr. Hart made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

PROMACTA TABLET (ORAL)

Urea Cycle Disorders, Oral

Dr. Figueroa made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

Recommendations for the PDL are:

PHEBURANE (ORAL)

Single Drug Reviews

Angiotensin Modulators

Dr. Figueroa made the motion to accept. Dr. Raven seconded the motion. There was no objection to the motion.

ENTRESTO SPRINKLE CAP (ORAL) – recommended NPD

Antiemetic/Antivertigo Agents

Dr. Figueroa made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

FOCINVEZ VIAL (INTRAVEN) - recommended NPD

Hypoglycemics, Incretin Mimetics/Enhancers

Dr. Black made the motion to accept. Dr. Figueroa seconded the motion. There was no objection to the motion.

SITAGLIPTIN/METFORMIN (ZITUVIMET) (AG) (ORAL) - recommended NPD

Immunosuppressives, Oral

Dr. Figueroa made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

MYHIBBIN SUSPENSION (ORAL) – recommended NPD

PAH Agents, Oral and Inhaled

Dr. Raven made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

OPSYNVI TABLET (ORAL) – recommended NPD

Opiate Dependence Treatment

Dr. Black made the motion to accept. Dr. Coleman seconded the motion. There was no objection to the motion.

REXTOVY SPRAY (NASAL) – recommended NPD

Spring Brand vs Generic Drug Reviews

Dr. Black made the motion to accept all of the changes below. Dr. Raven seconded the motion. There was no objection to the motion.

Acne Agents, Topical

RETIN-A CREAM (TOPICAL) –recommended NPD

Antibiotics, Inhaled

BETHKIS (INHALATION) –recommended NPD

Anticoagulants

PRADAXA (ORAL) –recommended NPD

Antiparasitics, Topical

NATROBA (TOPICAL) –recommended NPD

GI Motility, Chronic

AMITIZA (ORAL)—recommended NPD

H. Pylori Treatment

PYLERA (ORAL) – recommended NPD

Hypoglycemics, SGLT2

- FARXIGA (ORAL) –recommended NPD
- XIGDUO XR (ORAL) recommended NPD

Lipotropics, Other

VASCEPA (ORAL) –recommended NPD

Multiple Sclerosis Agents

- COPAXONE 20 MG/ML (SUBCUTANE.)- recommended NPD
- COPAXONE 40 MG/ML (SUBCUTANE.) –recommended NPD

Opiate Dependence Treatments

SUBOXONE FILM (SUBLINGUAL) –recommended NPD

Phosphate Binders

RENVELA TABLET (ORAL) –recommended NPD

Proton Pump Inhibitors

- NEXIUM SUSPENSION (ORAL) –recommended NPD
- PROTONIX SUSPENSION (ORAL) –recommended NPD

Ulcerative Colitis Agents

APRISO (ORAL) –recommended NPD

Other Business

Mr. Orlando indicated he is no longer chaired by the Board of Pharmacy under a chain pharmacist. He is now an independent pharmacist. According to the bylaws, the committee has to have one independent pharmacist and one chain pharmacist as chairs. Due to this, he has to relinquish his chair here. The new chairperson and the vice chairperson need to be elected. He nominated Dr. Comeau to chair the committee. All members voted in favor of Dr. Comeau as chairperson. Mr. Orlando nominated Dr. Black as vice chairperson. All members voted in favor of Dr. Black as vice chairperson.

Ms. Fontenot thanked Mr. Orlando for his service.

giw m.h

Next Steps

- **A.** Proposed Therapeutic Classes to be Reviewed at Next Meeting. Dr. Douiki presented the list of therapeutic classes to be reviewed at the spring 2025 P&T meeting.
- B. Next Meeting Date. Potential dates for the next committee meeting are May 4, 2025 or May 9, 2025.
- C. Public Testimony. None.

Adjournment

Mr. Orlando adjourned the meeting at or about 11:58 a.m.